Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Subscribe To Our Newsletter & Stay Updated
